However, recent advances in the field of anti-cancer therapies and mutations in oncogenic drivers (4), such as Epidermal Growth Factor Receptor (EGFR) mutations and Anaplastic Lymphoma Kinase (ALK) gene translocation, have improved the outlook in terms of both progression-free survival (PFS) and overall survival (OS), showing a promising future for advanced NSCLC therapy (5). This evidence concerns the gene ALK and cancer.